Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Semaglutide is a powerful aid for managing weight and Type 2 diabetes, but it’s not a free pass to stick with old habits—or skip taking action altogether. If you’ve been struggling with weight loss, ...

This aligns with findings from animal studies, where semaglutide ... are needed to fully understand their efficacy and mechanisms of action in humans. Glucagon-like peptide-1 (GLP-1): A hormone ...

The question of putative mechanisms of action continues to haunt psychopharmacology. Put simply, we know these drugs work, but we have very little idea how. We make guesses based on the ...

Although nicotine appears to be the beneficial ingredient, the precise mechanism of action remains unclear. As the cause of ulcerative colitis remains unknown there is much opportunity for ...

Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...